Numerous patients with type 2 diabetes still have poor glycemic control after receiving several classes of OHAs or newer and more expensive agents including dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 inhibitors. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.